Nippon Shinyaku gains Japanese rights to Labopharm's once-daily tramadol
This article was originally published in Scrip
The mid-sized Japanese company Nippon Shinyaku has acquired exclusive development and commercial rights in its home market to Labopharm's once-daily oral formulation of the analgesic tramadol.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.